223: Biologics in Lupus – Why, Who, and When?

Industry Presenter(s)

• AC

  Angela Crowley, MD

  Staff Physician and Rheumatologist
  Hinsdale Orthopaedics
  Hinsdale, Illinois, United States

  Disclosure information not submitted.
• AG

  Abdallah Geara, MD

  Assistant Professor of Clinical Medicine
  University of Pennsylvania
  Philadelphia, PA, United States

  Disclosure information not submitted.
• WC

  W. Winn Chatham, MD

  Professor of Medicine
  University of Alabama at Birmingham
  Birmingham, Alabama, United States

  Disclosure information not submitted.

Industry Moderator(s)

• AA

  Anca Askanase, MD, MPH

  Director
  Columbia University Medical Center
  New York, NY, United States

  Disclosure(s): Amgen: Advisor or Review Panel Member (Ongoing); AstraZeneca: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Aurinia: Advisor or Review Panel Member (Ongoing); Eli Lilly: Grant/Research Support (Ongoing); GlaxoSmithKlein(GSK): Advisor or Review Panel Member (Ongoing); Idorsia: Grant/Research Support (Ongoing); Janssen: Grant/Research Support (Ongoing); Pfizer: Grant/Research Support (Ongoing); UCB: Grant/Research Support (Ongoing)

We will explore how biologic therapies may help address key unmet needs in lupus. By modifying the immunologic mechanisms of disease, biologics have potential to change the course of disease, thereby minimizing disease activity, and slowing or preventing organ damage progression. The session will also discuss how clinicians can best identify the appropriate patients for biologic treatment.


Developed and offered by GSK